479 related articles for article (PubMed ID: 37991539)
1. Applications and advancements of nanoparticle-based drug delivery in alleviating lung cancer and chronic obstructive pulmonary disease.
De Rubis G; Paudel KR; Corrie L; Mehndiratta S; Patel VK; Kumbhar PS; Manjappa AS; Disouza J; Patravale V; Gupta G; Manandhar B; Rajput R; Robinson AK; Reyes RJ; Chakraborty A; Chellappan DK; Singh SK; Oliver BGG; Hansbro PM; Dua K
Naunyn Schmiedebergs Arch Pharmacol; 2024 May; 397(5):2793-2833. PubMed ID: 37991539
[TBL] [Abstract][Full Text] [Related]
2. Agarwood Oil Nanoemulsion Attenuates Cigarette Smoke-Induced Inflammation and Oxidative Stress Markers in BCi-NS1.1 Airway Epithelial Cells.
De Rubis G; Paudel KR; Manandhar B; Singh SK; Gupta G; Malik R; Shen J; Chami A; MacLoughlin R; Chellappan DK; Oliver BGG; Hansbro PM; Dua K
Nutrients; 2023 Feb; 15(4):. PubMed ID: 36839377
[TBL] [Abstract][Full Text] [Related]
3. Advanced Therapeutic Strategies for Chronic Lung Disease Using Nanoparticle-Based Drug Delivery.
Yhee JY; Im J; Nho RS
J Clin Med; 2016 Sep; 5(9):. PubMed ID: 27657144
[TBL] [Abstract][Full Text] [Related]
4. Novel drug delivery systems targeting oxidative stress in chronic obstructive pulmonary disease: a review.
Xu Y; Liu H; Song L
J Nanobiotechnology; 2020 Oct; 18(1):145. PubMed ID: 33076918
[TBL] [Abstract][Full Text] [Related]
5. Conventional and Nanotechnology Based Approaches to Combat Chronic Obstructive Pulmonary Disease: Implications for Chronic Airway Diseases.
Passi M; Shahid S; Chockalingam S; Sundar IK; Packirisamy G
Int J Nanomedicine; 2020; 15():3803-3826. PubMed ID: 32547029
[TBL] [Abstract][Full Text] [Related]
6. Chronic obstructive pulmonary disease and atherosclerosis: common mechanisms and novel therapeutics.
Brassington K; Selemidis S; Bozinovski S; Vlahos R
Clin Sci (Lond); 2022 Mar; 136(6):405-423. PubMed ID: 35319068
[TBL] [Abstract][Full Text] [Related]
7. The application of nanoparticles as advanced drug delivery systems in Attenuating COPD.
Jessamine V; Mehndiratta S; De Rubis G; Paudel KR; Shetty S; Suares D; Chellappan DK; Oliver BG; Hansbro PM; Dua K
Heliyon; 2024 Feb; 10(3):e25393. PubMed ID: 38356590
[TBL] [Abstract][Full Text] [Related]
8. Chronic obstructive pulmonary disease - diagnosis and management of stable disease; a personalized approach to care, using the treatable traits concept based on clinical phenotypes. Position paper of the Czech Pneumological and Phthisiological Society.
Zatloukal J; Brat K; Neumannova K; Volakova E; Hejduk K; Kocova E; Kudela O; Kopecky M; Plutinsky M; Koblizek V
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2020 Dec; 164(4):325-356. PubMed ID: 33325455
[TBL] [Abstract][Full Text] [Related]
9. Nucleic Acid-Based Therapeutics for Pulmonary Diseases.
Chen J; Tang Y; Liu Y; Dou Y
AAPS PharmSciTech; 2018 Nov; 19(8):3670-3680. PubMed ID: 30338490
[TBL] [Abstract][Full Text] [Related]
10. Inhaled Therapies for Asthma and Chronic Obstructive Pulmonary Disease.
Liang Y; Mak JCW
Curr Pharm Des; 2021; 27(12):1469-1481. PubMed ID: 33243107
[TBL] [Abstract][Full Text] [Related]
11. Nanoparticle-Based Drug Delivery System: The Magic Bullet for the Treatment of Chronic Pulmonary Diseases.
Pramanik S; Mohanto S; Manne R; Rajendran RR; Deepak A; Edapully SJ; Patil T; Katari O
Mol Pharm; 2021 Oct; 18(10):3671-3718. PubMed ID: 34491754
[TBL] [Abstract][Full Text] [Related]
12. Nano-based theranostics for chronic obstructive lung diseases: challenges and therapeutic potential.
Vij N
Expert Opin Drug Deliv; 2011 Sep; 8(9):1105-9. PubMed ID: 21711085
[TBL] [Abstract][Full Text] [Related]
13. New frontiers in the treatment of comorbid cardiovascular disease in chronic obstructive pulmonary disease.
Brassington K; Selemidis S; Bozinovski S; Vlahos R
Clin Sci (Lond); 2019 Apr; 133(7):885-904. PubMed ID: 30979844
[TBL] [Abstract][Full Text] [Related]
14. Biological effects and mechanisms of action of mesenchymal stem cell therapy in chronic obstructive pulmonary disease.
Jin Z; Pan X; Zhou K; Bi H; Wang L; Yu L; Wang Q
J Int Med Res; 2015 Jun; 43(3):303-10. PubMed ID: 25834280
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and Evaluation of Airway-Targeted PLGA-PEG Nanoparticles for Drug Delivery in Obstructive Lung Diseases.
Vij N
Methods Mol Biol; 2020; 2118():147-154. PubMed ID: 32152977
[TBL] [Abstract][Full Text] [Related]
16. Advancements in Chitosan-Based Nanoparticles for Pulmonary Drug Delivery.
Zacaron TM; Silva MLSE; Costa MP; Silva DME; Silva AC; Apolônio ACM; Fabri RL; Pittella F; Rocha HVA; Tavares GD
Polymers (Basel); 2023 Sep; 15(18):. PubMed ID: 37765701
[TBL] [Abstract][Full Text] [Related]
17. Adverse immunological responses against non-viral nanoparticle (NP) delivery systems in the lung.
de Braganca L; Ferguson GJ; Luis Santos J; Derrick JP
J Immunotoxicol; 2021 Dec; 18(1):61-73. PubMed ID: 33956565
[TBL] [Abstract][Full Text] [Related]
18. Progress in microRNA delivery.
Zhang Y; Wang Z; Gemeinhart RA
J Control Release; 2013 Dec; 172(3):962-74. PubMed ID: 24075926
[TBL] [Abstract][Full Text] [Related]
19. Biocomposite-based nanostructured delivery systems for the treatment and control of inflammatory lung diseases.
Mukherjee D; Bhatt S
Nanomedicine (Lond); 2022 May; 17(12):845-863. PubMed ID: 35477308
[TBL] [Abstract][Full Text] [Related]
20. Berberine-loaded engineered nanoparticles attenuate TGF-β-induced remodelling in human bronchial epithelial cells.
De Rubis G; Paudel KR; Liu G; Agarwal V; MacLoughlin R; de Jesus Andreoli Pinto T; Singh SK; Adams J; Nammi S; Chellappan DK; Oliver BGG; Hansbro PM; Dua K
Toxicol In Vitro; 2023 Oct; 92():105660. PubMed ID: 37591407
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
